MicroRNAs and other mechanisms regulate interleukin-17 cytokines and receptors
Jietang Mai1, Anthony Virtue1, Erin Maley1, Tran Tran1, Ying Yin1, Shu Meng1, Meghana Pansuria1, Xiaohua Jiang1,
Hong Wang1, Xiao-Feng Yang1
1
Department of Pharmacology and Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA 19140, U.S.A.
TABLE OF CONTENTS
- 1. Abstract
- 2. Introduction
- 3. Methods
- 3.1. Tissue expression profiles of genes encoding IL-17 cytokines, IL-17 receptors, RORC, and TRAF3IP2
- 3.2. Alternative spliced isoforms of IL-17 cytokines and IL-17 receptors
- 3.3. Presence of AU-rich elements and functional motifs in 3' untranslated regions of IL-17 cytokines and IL-17 receptors
- 3.4. Correlation of the ratios of tissue SAH versus SAM concentrations with the expression levels of IL-17 cytokine and receptor mRNA transcripts
- 3.5. MicroRNA Interaction with the mRNAs of IL-17 Cytokines and IL-17 Receptors
- 4. Results
- 4.1. Most of IL-17 cytokines are not constitutively expressed in the tissues examined, but several IL-17 receptors and TRAF3IP2 are ubiquitously expressed
- 4.2. Heart and vascular tissues are in the second tier of readiness to respond to IL-17 cytokine stimulation, which requires the upregulation of IL-17 receptor complex components
- 4.3. Alternative promoter and alternative splicing regulate the structures and expressions of IL-17 cytokines and receptors
- 4.4. Higher hypomethylation status is positively associated with higher expressions of IL-17 receptors and lower expression of IL-17d in mouse tissue
- 4.5. RNA binding proteins may regulate the mRNA stability and translation of IL-17 cytokines and receptors
- 4.6. MicroRNAs may regulate the mRNA stability and translation of IL-17 cytokines and receptors independently or via interaction with RNA binding protein-mediated mechanism
- 5. Discussion
- 6. Acknowledgements
- 7. References
1. ABSTRACT
Interleukin-17 cytokines are a family of pro-inflammatory cytokines. Our current studies found: i) IL-17 cytokines are not ubiquitously expressed, but several receptors and TRAF3IP2 are ubiquitously expressed in tissues with a few exceptions; ii) heart and vascular tissue are in the second tier of readiness to respond to IL-17 cytokine stimulation; iii) alternative transcription starting sites and alternative spliced isoforms are found in IL-17 cytokine and receptor transcripts; iv) higher hypomethylation status is associated with higher expressions of IL-17 receptors; v) the binding sites of several RNA binding proteins are found in the 3'UTRs of the mRNAs of IL-17 cytokines and receptors; and vi) numerous microRNA binding sites are statistically equivalent to that of experimentally verified microRNAs-mRNA interactions in the 3'UTRs of IL-17 cytokine and receptor mRNAs. These results suggest that mechanisms including alternative promoters, alternative splicing, RNA binding proteins, and microRNAs regulate the structures and expressions of IL-17 cytokines and receptors. These results provide an insight into the roles of IL-17 in mediating inflammation and immunity.